US 11,865,116 B2
Treatment of cancer with TG02
Thomas M. Estok, Williamsburg, VA (US); Eckard Weber, San Diego, CA (US); and Tracy Lee Lawhon, San Diego, CA (US)
Assigned to COTHERA BIOSCIENCE, INC., Grand Cayman (KY)
Appl. No. 16/087,966
Filed by Cothera Bioscience, Inc., Grand Cayman (KY)
PCT Filed Mar. 24, 2017, PCT No. PCT/US2017/023965
§ 371(c)(1), (2) Date Sep. 24, 2018,
PCT Pub. No. WO2017/165732, PCT Pub. Date Sep. 28, 2017.
Claims priority of provisional application 62/423,468, filed on Nov. 17, 2016.
Claims priority of provisional application 62/312,712, filed on Mar. 24, 2016.
Prior Publication US 2020/0323862 A1, Oct. 15, 2020
Int. Cl. A61K 31/529 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/44 (2006.01); A61K 31/454 (2006.01); A61K 31/495 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 38/07 (2006.01); A61K 39/395 (2006.01)
CPC A61K 31/529 (2013.01) [A61K 31/44 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 38/07 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method of treating a patient having cancer, the method comprising administering to the patient a therapeutically effective amount of (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene and radiotherapy, wherein MYC overexpression, MCL1 overexpression, or MYC and MCL1 overexpression is differentially present in a biological sample taken from the patient as compared with a biological sample taken from a subject of another phenotypic status.